ULTRAGENYX PHARMACEUTICAL INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 140.75 thousand shares for the 3-month period ending 2018-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2019-05-07
- ULTRAGENYX PHARMACEUTICAL INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2018-03-31 was 140.75K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month |
|---|---|
| 2018-03-31 | 140.75K shares 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |